Latest News and Press Releases
Want to stay updated on the latest news?
-
All four lead pipeline programs progressing towards expected clinical milestones in 2019Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine,...
-
10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at...
-
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
-
CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
-
Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®, VBI’s prophylactic Hepatitis B vaccineIn all three studies, seroprotection rates of more than 98%...
-
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
-
CAMBRIDGE, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
-
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...
-
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modificationEnrollment is complete in the high-dose study arm of Part AExpanded immunologic...
-
CAMBRIDGE, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...